Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

As part of a phase 1 or 2 study, this single-arm expansion cohort established the efficacy and safety of mosunetuzumab monotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) (received ≥2 previous lines of therapy). Intravenous mosunetuzumab was administered with...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartlett, Nancy L., Assouline, Sarit, Giri, Pratyush, Schuster, Stephen J., Cheah, Chan Y., Matasar, Matthew, Gregory, Gareth P., Yoon, Dok Hyun, Shadman, Mazyar, Fay, Keith, Yoon, Sung-Soo, Panizo, Carlos, Flinn, Ian, Johnston, Anna, Bosch, Francesc, Sehn, Laurie H., Wei, Michael C., Yin, Shen, To, Iris, Li, Chi-Chung, Huang, Huang, Kwan, Antonia, Penuel, Elicia, Budde, Lihua E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463194/
https://www.ncbi.nlm.nih.gov/pubmed/37067952
http://dx.doi.org/10.1182/bloodadvances.2022009260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463194/
https://www.ncbi.nlm.nih.gov/pubmed/37067952
http://dx.doi.org/10.1182/bloodadvances.2022009260

Ejemplares similares